Characterizing Adrenocortical Carcinoma in Brazil
Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort
This study looks at patients with adrenocortical carcinoma in Brazil to see how the disease affects them and what factors might influence their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Latin American Cooperative Oncology Group Academic / other |
| Locations | 10 sites (Fortaleza, Ceará and 9 other locations) |
| Trial ID | NCT06279442 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the clinical, pathological, and treatment data of patients diagnosed with adrenocortical carcinoma in Brazil since the year 2000. Given the notably higher incidence of this rare cancer in certain Brazilian regions, the study will focus on identifying prognostic factors and characterizing the cohort. Participants will be recruited from various hospitals that have treated patients with this condition, allowing for a comprehensive analysis of the disease's impact in the local population.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a diagnosis of adrenocortical carcinoma and clinical evaluations at the participating institutions.
Not a fit: Patients with insufficient clinical or pathological data in their medical records will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of adrenocortical carcinoma and improve patient management strategies.
How similar studies have performed: While adrenocortical carcinoma studies are limited, the unique focus on the Brazilian population and the TP53-R337H mutation provides a novel approach to understanding this condition.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants over 18 years old; * Diagnosis of adrenocortical carcinoma with at least one clinical evaluation at the reference institution; * Initial diagnosis or recurrence from the year 2000 onwards. Exclusion Criteria: * Participants with insufficient clinical or pathological data in the medical records.
Where this trial is running
Fortaleza, Ceará and 9 other locations
- Pronutrir - Suporte Nutricional e Quimioterapia — Fortaleza, Ceará, Brazil (Recruiting)
- Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho — São Luís, Maranhão, Brazil (Recruiting)
- Hospital Erasto Gaertner — Curitiba, Paraná, Brazil (Recruiting)
- Hospital Santa Joana Recife (Instituto Américas PE) — Recife, Pernambuco, Brazil (Recruiting)
- UOPECCAN - Hospital do Câncer de Cascavel — Cascavel, Santa Catarina, Brazil (Recruiting)
- FUNFARME - Hospital de Base de São José do Rio Preto — São José do Rio Preto, São Paulo, Brazil (Recruiting)
- INCA - Instituto Nacional de Câncer — Rio de Janeiro, Brazil (Recruiting)
- BP - A Beneficência Portuguesa de São Paulo — São Paulo, Brazil (Recruiting)
- HAOC - Hospital Alemão Oswaldo Cruz — São Paulo, Brazil (Recruiting)
- A.C. Camargo Cancer Center — São Paulo, Brazil (Recruiting)
Study contacts
- Principal investigator: Milena Shizue Tariki — Latin American Cooperative Oncology Group
- Study coordinator: Giana Blume Corssac
- Email: giana.corssac@lacogcancerresearch.org
- Phone: +55 51 3384 5334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.